A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study

Tove Christensen

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Julian Gold, The Albion Centre, The University of Sydney School of Medicine, Sydney, NSW, Australia
Monica Marta, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Ute C Meier, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Tove Christensen
David Miller, Institute of Neurology, University College London, United Kingdom
Daniel Altmann, Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, United Kingdom
David Holden, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Lucia Bianchi, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Rocco Adiutori, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
David MacManus, Institute of Neurology, University College London, United Kingdom
Tarek Yousry, Institute of Neurology, University College London, United Kingdom
Klaus Schmierer, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Benjamin Turner, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom
Gavin Giovannoni, Blizard Institute, Barts and the London School of Medicine and Dentistry, United Kingdom

Originalsprog	Engelsk
Tidsskrift	Multiple Sclerosis and Related Disorders
Vol/bind	24
Sider (fra-til)	123-128
ISSN	2211-0348
DOI	https://doi.org/10.1016/j.msard.2018.06.002
Status	Udgivet - 2018

ID: 129593752

Department of Biomedicine